Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease
NCT07409597, Not applicable, Not yet recruiting, University Hospital, Angers
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease | ClinicalTrials.gov |
| NCT number | NCT07409597 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Angers | ClinicalTrials.gov |
| Conditions | Huntington Disease, Autobiographical Memory | ClinicalTrials.gov |
| Interventions | neuropsychological tests, Eye tracker use | ClinicalTrials.gov |
| First posted | 2026-02-13 | ClinicalTrials.gov |
| Last updated | 2026-04-06 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD, through analysis of the specificity | inclusion | It will be assessed using the TEMPau specificity scale. This scale uses a Likert scale ranging from 0 to 4 points (0: no response or general information; 1: vague event without spatial-temporal context; 2: generic or specific event without spatial-temporal context; 3: specific event in a non-detailed spatial-temporal context; 4: specific event in a detailed spatial-temporal context). This scale allows two main scores to be collected for each period of life explored: 1) an overall autobiographical memory score counting all events, regardless of their nature (max.: 3 x 1 = 3) and 2) a strictly episodic score, counting only memories that meet all the criteria for episodicity, rated 4 (max.: 3 x 4 = 12). The scale also provides: 1) an overall autobiographical memory score for all four life periods explored (max.: 3 x 4 = 12) and an overall strictly episodic score, counting only memories that meet all the criteria for episodicity across all four periods, rated 4 (max.: 12 x 4 = 48). | ClinicalTrials.gov |
| Primary | Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the phenomenology | inclusion | self-questionnaire comprising eight items, measured on a Likert scale ranging from 1 to 4 points (1: no, that is completely untrue; 2: no, that is rather untrue; 3: yes, that is rather true; 4: yes, that is completely true). The 8 items are as follows: 1: I felt like I was reliving the original event; 2: I felt like I was travelling back in time to the moment when the event happened; 3: I don't just know that this event happened, I remember actually experiencing it; 4: I believe that the event in my memory actually happened as I remember it; 5: I can see and hear elements of the event in my mind; 6: I can now feel the emotions I felt when the event happened; 7: I can remember where the event took place; I can remember the time when the event occurred. This scale allows a phenomenological score to be obtained for each period of life explored (max.: 3 x 8 x 4 = 96) and an overall phenomenological score for all four periods of life explored (max.: 3 x 8 x 4 x 4 = 380). | ClinicalTrials.gov |
| Primary | Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the self-defined nature | inclusion | Each memory is evaluated according to six empirically based dimensions: 1. the specificity of the event (rated from 0 to 4 according to TEMPau criteria, with 0 = extended or semantic memory, 4 = unique event, situated in time and space), 2. identity relevance ('This memory reflects an important part of who I am') 3. the presence of a lasting personal conflict or theme ('This memory is linked to an important theme or conflict in my life') 4. emotional intensity ('This memory expresses a very strong or striking emotion') 5. reflective integration ('This memory has helped me learn a personal lesson') 6. frequency of mental access ('This is a memory I often think back on or talk about regularly') The last five dimensions are assessed by self-questionnaire, on a Likert scale ranging from 1 to 4 (1 = not at all, 4 = completely). This combination gives an overall SDM score ranging from 5 (weakly self-defined memory) to 24. | ClinicalTrials.gov |
| Primary | Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the emotional valence | inclusion | It will be assessed using the 'Then' and 'Now' scale, which consists of asking the subject to evaluate (self-questionnaire), for each memory, on a Likert scale ranging from -3 to 3, how they felt at the time the event occurred and how they feel when they recall it. | ClinicalTrials.gov |
| Primary | Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the degree of integration of memories | inclusion | It will be assessed qualitatively using the definitions provided by Blagov and Singer (2004): * Integrative memories: There is a shift away from narrative events and descriptions to make an additional statement about the importance or significance of the memory to the individual. A meaningful statement must go beyond simply saying that the memory is 'important', 'the most painful' or 'a memory I will never forget'. There must be an indication of why the memory is important and moving. * Non-integrative memories: These are discussed in the manual and do not meet the requirements of integrative memories. | ClinicalTrials.gov |
| Secondary | To study the variation in pupil dilation characteristics during the recall of autobiographical memories. | inclusion | Measured in millimeters (between 1.5 to 8 mm) with Pupil Labs Core monocular device | ClinicalTrials.gov |
| Secondary | To study the variation of eye movements during the recall of autobiographical memories (number). | inclusion | number of fixation and saccades measured with Pupil Labs Core monocular device | ClinicalTrials.gov |
| Secondary | To study the variation of eye movements during the recall of autobiographical memories (duration). | inclusion | duration of fixation and saccades measured with Pupil Labs Core monocular device | ClinicalTrials.gov |
| Secondary | Study the links between participants' temporal perspective (past, present, future)and their autobiographical performance | inclusion | assessed using the ZTPI-short (Zimbardo Time Perspective Inventory - short version) | ClinicalTrials.gov |
| Secondary | analyse the current representation of the self (psychological, social, physical) | inclusion | identity fluency task: through spontaneous verbal productions | ClinicalTrials.gov |
| Secondary | Evaluate the functional dimension of autobiographical memory (why we use it) | inclusion | It will be assessed using the TALE-15 (Thinking About Life Experiences) questionnaire | ClinicalTrials.gov |
| Secondary | Investigate clinical and cognitive data from routine assessments with UHDRS | inclusion | using Unified Huntington's Disease Rating Scale; This scale is divided into several subscales grouping together different tests assessing: motor difficulties (dysarthria, dystonia, choreic movements, bradykinesia, gait disorders, etc.), cognitive difficulties \[flexibility (literal verbal fluency), processing speed (Symbol Digit Modalities Test), inhibition (Stroop task)\], level of independence, and functional difficulties. The TFC (Total Functional Capacity) is a specific subscale of the UHDRS that assesses patients' functional independence. It takes into account five areas: occupational capacity, financial management, domestic management, independence in activities of daily living, and degree of care required. The overall score ranges from 0 (complete dependence) to 13 (complete independence). A high score indicates preserved independence, while a low score reflects a significant loss of independence. TFC is a benchmark indicator of disease severity and progression. | ClinicalTrials.gov |
| Secondary | Investigate clinical and cognitive data from routine assessments with MMSE | inclusion | overall efficiency measured using Mini Mental Scale examination | ClinicalTrials.gov |
| Secondary | Investigate clinical and cognitive data from routine assessments with categorical fluency | inclusion | flexibility measured using categorical fluency | ClinicalTrials.gov |
| Secondary | Investigate clinical and cognitive data from routine assessments with Trail making Test | inclusion | flexibility measured using Trail making Test | ClinicalTrials.gov |
| Secondary | Investigate clinical and cognitive data from routine assessments with PBA-s | inclusion | Behaviour troubles measured with Problem Behaviours Assesment scale | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)